Targeting hepatocyte growth factor/c-mesenchymal-epithelial transition factor axis in hepatocellular carcinoma:...

Area of Science:

• Oncology
• Hepatology
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) remains a major global cause of cancer mortality.
• Current treatments for advanced HCC, including targeted therapies, offer limited efficacy.
• Novel therapeutic strategies are urgently needed to improve patient outcomes.

Purpose of the Study:

• To review the role of the hepatocyte growth factor/c-mesenchymal-epithelial transition factor (HGF/c-Met) axis in HCC.
• To evaluate the therapeutic potential of inhibiting the HGF/c-Met pathway.
• To analyze inconsistencies in HGF/c-Met research and propose future directions.

Main Methods:

• Literature review of evidence on HGF/c-Met as a prognostic marker in HCC.
• Discussion of in vitro anti-c-Met therapies.
• Summary of clinical trial outcomes for c-Met inhibitors.
• Analysis of HGF/c-Met expression variability in published studies.

Main Results:

• The HGF/c-Met axis is implicated in HCC tumor progression and serves as a prognostic marker.
• In vitro studies demonstrate the efficacy of anti-c-Met therapies.
• Clinical trials of c-Met inhibitors have yielded varied results, necessitating further investigation.
• Inconsistencies in HGF/c-Met findings can be explained by biological and methodological factors.

Conclusions:

• The HGF/c-Met pathway is critical for HCC progression and growth.
• Inhibiting the HGF/c-Met pathway represents a promising strategy for novel HCC treatments.
• Further research is warranted to optimize anti-c-Met therapies for HCC patients.